Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

NCT01466062 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infection

Interventions

DRUG: Palivizumab

Sponsor

AbbVie (prior sponsor, Abbott)